SLC3A2 and breast carcinoma: SLC7A11 (xCT), SLC3A2 (xCT), and GPX4 expression have been reported to be elevated in a subset of TNBC breast cancer models predicting response to erastin (xCT inhibitor) and RSL3 (GPX4 inhibitor) [17].